

RESPONSE UNDER 37 CFR 1.116  
 EXPEDITED PROCEDURE  
 EXAMINING GROUP 1623

PATENT

Rev 07/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
 CENTRAL FAX CENTER

OCT 12 2006

In re application : Mitchell P. Fink et al.  
 Application No. : 10/659,063  
 Filed : September 10, 2003  
 Confirmation No. : 3827  
 For : EXTRACELLULAR NAD+ AND CADPR AS POTENT  
 ANTI-INFLAMMATORY AGENTS  
 Examiner : Henry, Michael C.  
 Attorney's Docket : UPITT-008XX

TC Art Unit: 1623

Do  
 not  
 enter

M.C.H  
 11/20/06

By: Holliday C. Heine  
 Holliday C. Heine, Ph.D.  
 Registration No. 34,346  
 Attorney for Applicant(s)

AMENDMENT PURSUANT TO 37 C.F.R. §1.116

Via Facsimile  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

In response to the final Office Action dated June 12, 2006,  
 in the above-identified patent application, please amend the  
 claims as follows.

WEINTRAUB, SCHNEIDER,  
 CACHTAN & LEROVICH LLP  
 TEL. (617) 453-2390  
 FAX. (617) 451-0313